Wee1 kinase inhibitors and methods of making and using the same
View Patent ↗A compound, or a pharmaceutically acceptable salt thereof, having a chemical structure of formula (I) or formula (II), and methods of using these compounds to treat cancer in an individual.
1. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
2. A pharmaceutical composition comprising a compound of claim 1 , and at least one pharmaceutically acceptable additive.
3. A method of treating or ameliorating cancer in a subject, the method comprising administering a therapeutically effective amount of a compound of claim 1 to the subject, wherein the cancer is selected from medulloblastoma, primitive neuroectodermal tumors (PNET), pediatric glioblastoma multiforme (GBM), and pilocytic astrocytoma (PA).
4. The method of claim 3 , wherein the compound is administered to the subject within a pharmaceutical composition.
5. The method of claim 4 , wherein the pharmaceutical composition is a mono-phasic pharmaceutical composition suitable for parenteral or oral administration consisting essentially of a therapeutically effective amount of the compound, and a pharmaceutically acceptable additive.
6. The method of claim 4 , wherein the pharmaceutical composition is administered with any one of cisplatin, capecitabine, carboplatin, cyclophosphamide, cytarabine, dauoribicin, docetaxel, doxorubicin, 5-fluorouracil, gemcitabine, methotrexate, paclitaxel, premetrexed, irinotecan temozolomide, topotecan, radiation, or combinations thereof.
7. The method of claim 4 , wherein the pharmaceutical composition is administered in conjunction with at least one of cisplatin, cytarabine, or temozolomide.
8. The method of claim 3 , wherein the cancer is medulloblastoma.
9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is:
10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is:
11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is:
12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is:
13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is: